Pub Date : 2023-04-20DOI: 10.2174/2468187313666230420075952
Akanksha Patel, A. Dharamsi
Voriconazole (VRZ) is widely used for fungal keratitis topically. It is sparingly water soluble and has limited permeability which can lead to poor bioavailability. Nanostructured Lipid Carriers (NLCs) are selected as a carrier for voriconazole as they increase solubility while the lipidic character of the formulation facilitates permeation. o To develop a new method of preparation of lipidic nanoparticles o To apply Quality by design and risk-based approach to find variables o To optimize variables and find the design space o To evaluate and characterize the optimized formulation The present study is an attempt to address the challenges in the formulation of NLCs using a high-speed homogenizer. Quality by Design approach was used to find the material attributes and process parameters playing a significant role in the formulation development. Quality Target product profile was prepared, and failure mode and effect analysis was performed for a better understanding of the risks, ways to alleviate risks, and finally, to propose a control strategy. The formulation was optimized by using 3-levels 3-factors central composite design, and design space was obtained by using graphical optimization. The morphology of the particles was studied by using Transmission Electron Microscope. In vitro drug release study was performed using Franz diffusion cell. The amount of solid lipid, solid lipid to total lipid ratio, and concentration of surfactant were found to be high risk variables and their effects on the product quality were examined using Central composite design considering particle size, particle size distribution and %entrapment efficiency as dependent variables. Optimized NLC had a particle size of 72.58 nm with PDI 0.137 and %entrapment efficiency of 78.79%. The in vitro drug release study showed sustained drug release over the period of 24 hrs and followed the Higuchi model with a fickian diffusion mechanism The present study successfully explored QbD along with Risk-based approach for the development of voriconazole containing lipidic nanoparticles.
{"title":"Voriconazole Loaded Lipidic Nanoparticles for Ophthalmic Delivery: Development Using QbD Combined with Risk-based Approach","authors":"Akanksha Patel, A. Dharamsi","doi":"10.2174/2468187313666230420075952","DOIUrl":"https://doi.org/10.2174/2468187313666230420075952","url":null,"abstract":"\u0000\u0000Voriconazole (VRZ) is widely used for fungal keratitis topically. It is sparingly water soluble and has limited permeability which can lead to poor bioavailability. Nanostructured Lipid Carriers (NLCs) are selected as a carrier for voriconazole as they increase solubility\u0000while the lipidic character of the formulation facilitates permeation.\u0000\u0000\u0000\u0000o To develop a new method of preparation of lipidic nanoparticles\u0000o To apply Quality by design and risk-based approach to find variables\u0000o To optimize variables and find the design space\u0000o To evaluate and characterize the optimized formulation\u0000\u0000\u0000\u0000The present study is an attempt to address the challenges in the formulation of NLCs using a high-speed homogenizer. Quality by Design approach was used to find the material attributes\u0000and process parameters playing a significant role in the formulation development. Quality Target\u0000product profile was prepared, and failure mode and effect analysis was performed for a better understanding of the risks, ways to alleviate risks, and finally, to propose a control strategy. The formulation was optimized by using 3-levels 3-factors central composite design, and design space was\u0000obtained by using graphical optimization. The morphology of the particles was studied by using\u0000Transmission Electron Microscope. In vitro drug release study was performed using Franz diffusion\u0000cell.\u0000\u0000\u0000\u0000The amount of solid lipid, solid lipid to total lipid ratio, and concentration of surfactant\u0000were found to be high risk variables and their effects on the product quality were examined using\u0000Central composite design considering particle size, particle size distribution and %entrapment\u0000efficiency as dependent variables. Optimized NLC had a particle size of 72.58 nm with PDI 0.137\u0000and %entrapment efficiency of 78.79%. The in vitro drug release study showed sustained drug\u0000release over the period of 24 hrs and followed the Higuchi model with a fickian diffusion mechanism\u0000\u0000\u0000\u0000The present study successfully explored QbD along with Risk-based approach for the\u0000development of voriconazole containing lipidic nanoparticles.\u0000","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44038107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-20DOI: 10.2174/2468187313666230320115153
C. Chauhan, Rutvi Agrawal, Akash Garg
Micellization is the process of formation of micelles using different polymers mainly pluronic (F127, F123, etc.). Polymers are used to formulate polymeric micelles that provide physical and chemical stability of drugs that are encapsulated into them. Moreover, the drugs are encapsulated in the core portion (hydrophobic inner) of micelles and another portion is the shell portion (hydrophilic outer) which provides hydrophilicity to the hydrophobic drug. Delivery of hydrophobic drugs by micelles is easy and preferred due to the nano size structure, well association, low toxicity, biocompatible, well core structure, and a high stability. Several methods of preparation of micelles such as - thin film hydration, solvent evaporation, dialysis, and direct dissolution are discussed here. Micelles formulations in pharmaceutical industries are preferred because they enhance the solubility and bioavailability of drugs of BCS class II and IV. This review focuses on various strategies to overcome the problems related to poor aqueous solubility and bioavailability of drugs, micellar solubilization, and application of micelles for various drug delivery. It also includes future considerations for the development of various polymeric micelles-based drug formulations.
{"title":"A Snapshot on Polymeric Micelles as a carrier for Drug Delivery","authors":"C. Chauhan, Rutvi Agrawal, Akash Garg","doi":"10.2174/2468187313666230320115153","DOIUrl":"https://doi.org/10.2174/2468187313666230320115153","url":null,"abstract":"\u0000\u0000Micellization is the process of formation of micelles using different polymers mainly pluronic (F127, F123, etc.). Polymers are used to formulate polymeric micelles that provide physical and chemical stability of drugs that are encapsulated into them. Moreover, the drugs are encapsulated in the core portion (hydrophobic inner) of micelles and another portion is the shell portion (hydrophilic outer) which provides hydrophilicity to the hydrophobic drug. Delivery of hydrophobic drugs by micelles is easy and preferred due to the nano size structure, well association, low toxicity, biocompatible, well core structure, and a high stability. Several methods of preparation of micelles such as - thin film hydration, solvent evaporation, dialysis, and direct dissolution are discussed here. Micelles formulations in pharmaceutical industries are preferred because they enhance the solubility and bioavailability of drugs of BCS class II and IV. This review focuses on various strategies to overcome the problems related to poor aqueous solubility and bioavailability of drugs, micellar solubilization, and application of micelles for various drug delivery. It also includes future considerations for the development of various polymeric micelles-based drug formulations.\u0000","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48611064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.2174/246818731301230717101025
Maria J. Blanco-Prieto
{"title":"Meet the Editorial Board Member","authors":"Maria J. Blanco-Prieto","doi":"10.2174/246818731301230717101025","DOIUrl":"https://doi.org/10.2174/246818731301230717101025","url":null,"abstract":"","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":"201 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135469517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-28DOI: 10.2174/2468187313666230228102211
A. Jadhav, Bharat T Agiwale, Chetan R Sonawane, S. Ahirrao, Smita Prakash Kakad, Sanjay J. Kshirsagar, Mrudula H. Bele
In the last decade, the onset of neurodegenerative diseases (ND) has been strongly widespread due to the rapid increase in the world population. There are many neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, spinal muscular atrophy, Levy body disease, etc. Alzheimer’s disease and Parkinson’s disease are most commonly found. Neurodegenerative diseases occur due to the degradation of neurons in the brain and the spinal cord. The diagnosis of both diseases has increased, however, the successful treatment is still very limited because of the lower ability of the drug to cross the blood-brain barrier (BBB). It is a big challenge to deliver the drug to the brain, because only small and lipid-soluble agents cross the BBB, by considering this assumption, the liposomal drug delivery system is considered one of the effective treatments in neurodegenerative diseases. Liposomes are considered to be an ideal carrier as they are flexible, biocompatible, and can carry different types of therapeutic molecules across the BBB. This review focus on the potential use of lipid delivery system in the treatment of neurodegenerative diseases and the application of liposomes in Alzheimer's disease and Parkinson’s disease.
{"title":"Liposomal Drug Delivery System as An Emerging Technique for Treatment Of Neurodegenerative Diseases","authors":"A. Jadhav, Bharat T Agiwale, Chetan R Sonawane, S. Ahirrao, Smita Prakash Kakad, Sanjay J. Kshirsagar, Mrudula H. Bele","doi":"10.2174/2468187313666230228102211","DOIUrl":"https://doi.org/10.2174/2468187313666230228102211","url":null,"abstract":"\u0000\u0000In the last decade, the onset of neurodegenerative diseases (ND) has been strongly widespread due to the rapid increase in the world population. There are many neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, spinal muscular atrophy, Levy body disease, etc. Alzheimer’s disease and Parkinson’s disease are most commonly found. Neurodegenerative diseases occur due to the degradation of neurons in the brain and the spinal cord. The diagnosis of both diseases has increased, however, the successful treatment is still very limited because of the lower ability of the drug to cross the blood-brain barrier (BBB). It is a big challenge to deliver the drug to the brain, because only small and lipid-soluble agents cross the BBB, by considering this assumption, the liposomal drug delivery system is considered one of the effective treatments in neurodegenerative diseases. Liposomes are considered to be an ideal carrier as they are flexible, biocompatible, and can carry different types of therapeutic molecules across the BBB. This review focus on the potential use of lipid delivery system in the treatment of neurodegenerative diseases and the application of liposomes in Alzheimer's disease and Parkinson’s disease.\u0000","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41522298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-13DOI: 10.2174/2468187313666230213121011
Niranjan Kaushik, N. Mishra, Pramod Kumar Sharma, M. Alam
In nanoemulsions, both oil and water droplets are stabilised by an amphiphilic surfactant. Ultrafine dispersions with varying drug loading, viscoelastic properties, and aesthetic characteristics may be useful for the administration of medication. A 20–500-nanometer droplet size range for nanoemulsions has been established. The biological behavior of a nanoemulsions formulation is heavily influenced by its droplet diameter and surface properties. Small droplet size results in clear emulsions; therefore, the appearance of the product is unaffected even by the addition of an oil phase. Nanoemulsions are oil-in-water dispersions that are transparent or translucent and are stabilized by an interfacial layer of surfactants and cosurfactant particles with droplet size smaller than 100 nm. New nanoscience-based technologies are becoming increasingly popular as a means of improving food safety, quality, and nutrition. In this field, nanoemulsions have been a key focus since they can be readily manufactured using current food components and technology. Food nanoemulsions, which are tiny oil droplets distributed in water, are being used as delivery methods for a variety of hydrophobic compounds, including nutrients, nutraceuticals, antioxidants, and antimicrobial agents. The present review is focused on the formulation, characterization, and applications of nanoemulsions.
{"title":"Nano Emulsion Drug Delivery System: A Review","authors":"Niranjan Kaushik, N. Mishra, Pramod Kumar Sharma, M. Alam","doi":"10.2174/2468187313666230213121011","DOIUrl":"https://doi.org/10.2174/2468187313666230213121011","url":null,"abstract":"\u0000\u0000In nanoemulsions, both oil and water droplets are stabilised by an amphiphilic surfactant. Ultrafine dispersions with varying drug loading, viscoelastic properties, and aesthetic characteristics may be useful for the administration of medication. A 20–500-nanometer droplet size range for nanoemulsions has been established. The biological behavior of a nanoemulsions formulation is heavily influenced by its droplet diameter and surface properties. Small droplet size results in clear emulsions; therefore, the appearance of the product is unaffected even by the addition of an oil phase. Nanoemulsions are oil-in-water dispersions that are transparent or translucent and are stabilized by an interfacial layer of surfactants and cosurfactant particles with droplet size smaller than 100 nm. New nanoscience-based technologies are becoming increasingly popular as a means of improving food safety, quality, and nutrition. In this field, nanoemulsions have been a key focus since they can be readily manufactured using current food components and technology. Food nanoemulsions, which are tiny oil droplets distributed in water, are being used as delivery methods for a variety of hydrophobic compounds, including nutrients, nutraceuticals, antioxidants, and antimicrobial agents. The present review is focused on the formulation, characterization, and applications of nanoemulsions.\u0000","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41450418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-17DOI: 10.2174/2468187313666230117163425
S. Bhatt, Sumit Sharma, J. Sharma, Manish Kumar, R. Verma, Deepak Kaushik
Drugs with high first-pass metabolism or that are susceptible to enzymatic degradation can be administered through the nasal route to avoid their degradation. Lurasidone exhibits less toxicity and side effects as compared to its sister drugs like risperidone, ziprasidone, clozapine, etc. The present study aimed to develop Lurasidone loaded niosomes for nasal delivery. Lurasidone niosomes were developed by adapting the ether injection method and optimized using a central composite design. In vitro and in vivo studies were conducted using optimized formulation. The findings showed that the optimized formulation exhibited a particle size of 159.02 ± 0.58 nm and an entrapment efficiency of 91.6 ± 1.6 %. The findings from the nasal histopathological analysis revealed that the optimized formulation was non-irritant and non-toxic for nasal mucosa. The findings from in vitro studies revealed 94.61 ± 0.27 % of drug release from optimized formulation F7 throughout 24 hrs. The findings of in vivo (Albino Wistar rats) studies demonstrated that various pharmacokinetic parameters (Cmax, Tmax, AUC(0-24), T1/2, Vd and Cl) and pharmcodynamic parameters (conditioned avoidance response, biochemical estimation using oxidative markers such as superoxide dismutase, malondialdehyde and glutathione) were significantly improved compared to marketed tablets (Lurasid® 40 mg) and pure drug suspension. Optimized formulation F-7 exhibited 4.9 times more bioavailability than that of pure drug suspension following intranasal administration. These findings indicate that nasal niosomal formulation of Lurasidone HCl is a promising nanoplatform for enhancing the overall performance of Lurasidone. These results could open new avenues into the future of nanomedicine.
{"title":"Engineering of Lurasidone hydrochloride loaded niosomes for enhancing the antipsychotic potential for nasal administration","authors":"S. Bhatt, Sumit Sharma, J. Sharma, Manish Kumar, R. Verma, Deepak Kaushik","doi":"10.2174/2468187313666230117163425","DOIUrl":"https://doi.org/10.2174/2468187313666230117163425","url":null,"abstract":"\u0000\u0000Drugs with high first-pass metabolism or that are susceptible to enzymatic degradation can be administered through the nasal route to avoid their degradation. Lurasidone exhibits less toxicity and side effects as compared to its sister drugs like risperidone, ziprasidone, clozapine, etc.\u0000\u0000\u0000\u0000The present study aimed to develop Lurasidone loaded niosomes for nasal delivery.\u0000\u0000\u0000\u0000Lurasidone niosomes were developed by adapting the ether injection method and optimized using a central composite design. In vitro and in vivo studies were conducted using optimized formulation.\u0000\u0000\u0000\u0000The findings showed that the optimized formulation exhibited a particle size of 159.02 ± 0.58 nm and an entrapment efficiency of 91.6 ± 1.6 %. The findings from the nasal histopathological analysis revealed that the optimized formulation was non-irritant and non-toxic for nasal mucosa. The findings from in vitro studies revealed 94.61 ± 0.27 % of drug release from optimized formulation F7 throughout 24 hrs. The findings of in vivo (Albino Wistar rats) studies demonstrated that various pharmacokinetic parameters (Cmax, Tmax, AUC(0-24), T1/2, Vd and Cl) and pharmcodynamic parameters (conditioned avoidance response, biochemical estimation using oxidative markers such as superoxide dismutase, malondialdehyde and glutathione) were significantly improved compared to marketed tablets (Lurasid® 40 mg) and pure drug suspension. Optimized formulation F-7 exhibited 4.9 times more bioavailability than that of pure drug suspension following intranasal administration.\u0000\u0000\u0000\u0000These findings indicate that nasal niosomal formulation of Lurasidone HCl is a promising nanoplatform for enhancing the overall performance of Lurasidone. These results could open new avenues into the future of nanomedicine.\u0000","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46790689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-06DOI: 10.2174/2468187313666230106153044
LR Jaidev, L. Chede
One of the major limitations to drug delivery at mucosal administration sites is the limited retention of the dose at the tissue surface. Bioadhesive delivery systems increase the residence time/retention of the dosage form at the application site. To retain the drug at the site of administration for improved absorption and ease of administration, the identification of polymer systems based on site-specific physiological conditions is important. This review outlines diverse kinds of polymer systems and their mechanism of mucoadhesion. This review presents a brief description of bioadhesive strategies for the formulation and development of a buccal and esophageal delivery system based on its site-specific physiological considerations.
{"title":"Bioadhesive Systems Targeting Site-Specific Mucosal Delivery","authors":"LR Jaidev, L. Chede","doi":"10.2174/2468187313666230106153044","DOIUrl":"https://doi.org/10.2174/2468187313666230106153044","url":null,"abstract":"\u0000\u0000One of the major limitations to drug delivery at mucosal administration sites is the limited retention of the dose at the tissue surface. Bioadhesive delivery systems increase the residence time/retention of the dosage form at the application site. To retain the drug at the site of administration for improved absorption and ease of administration, the identification of polymer systems based on site-specific physiological conditions is important. This review outlines diverse kinds of polymer systems and their mechanism of mucoadhesion. This review presents a brief description of bioadhesive strategies for the formulation and development of a buccal and esophageal delivery system based on its site-specific physiological considerations.\u0000","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45185410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-06DOI: 10.2174/2468187313666230106104528
A. Chaudhary, Urvashi Garg, Shobhit Kumar
Nanoformulations are a novel method of administration of the drug, approved by the USFDA. These formulations are able to deliver the drug molecules to the target site more effectively and efficiently. So, this technology has found a vital role in cancer therapy. The nanoformulations can be of many types: Liposomes, Micelles, Nano-emulsions, Dendrimers, etc. Many studies have been done on nanoformulations and it is revealed that a number of natural products like curcumin, thymoquinone and papaverine, which contain anti-cancer activity, are more effective in nanoformulation form. This review discusses the nanoformulations, their applications, uses and advantages in cancer therapy along with the anti-cancer drugs that are administered as nanoformulations.
{"title":"Nanoformulations Of Anti-Cancer Agents: Present Status & Future Directions","authors":"A. Chaudhary, Urvashi Garg, Shobhit Kumar","doi":"10.2174/2468187313666230106104528","DOIUrl":"https://doi.org/10.2174/2468187313666230106104528","url":null,"abstract":"\u0000\u0000Nanoformulations are a novel method of administration of the drug, approved by the USFDA. These formulations are able to deliver the drug molecules to the target site more effectively and efficiently. So, this technology has found a vital role in cancer therapy. The nanoformulations can be of many types: Liposomes, Micelles, Nano-emulsions, Dendrimers, etc. Many studies have been done on nanoformulations and it is revealed that a number of natural products like curcumin, thymoquinone and papaverine, which contain anti-cancer activity, are more effective in nanoformulation form. This review discusses the nanoformulations, their applications, uses and advantages in cancer therapy along with the anti-cancer drugs that are administered as nanoformulations.\u0000","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46349937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-19DOI: 10.2174/2468187313666221219150315
S. Kashaw, Surbhi Tomar, Vaibhav Rajoriya, P. Sahu, Shivangi Agarwal, S. P. Vyas
Successful drug delivery with a carrier into the targeted organelles (nucleus, mitochondria, lysosomes, etc.) is vital for achieving effective disease treatment. Nanoparticle (NP) based drug delivery systems (NDDSs) depend on targeted delivery and are mainly focused on cell-membrane targeting. In this review, we summarize research on multifunctional NPs with organelle-specific drug delivery. Different effective strategies are proposed for these nanoparticles functionalizing by altering their chemical composition or by functional groups grafting onto their surface for improving the ability of organelle targeting. Only when the released concentration of drugs becomes high enough will they interact with specific organelles by molecular targets to induce apoptosis of tumor cells. One of the prime goals for drug delivery research targeted is Organelle-specific delivery.
{"title":"0multifunctional Nanoparticles For Organelle-Specific Targeted Drug Delivery In Cancer Therapy","authors":"S. Kashaw, Surbhi Tomar, Vaibhav Rajoriya, P. Sahu, Shivangi Agarwal, S. P. Vyas","doi":"10.2174/2468187313666221219150315","DOIUrl":"https://doi.org/10.2174/2468187313666221219150315","url":null,"abstract":"\u0000\u0000Successful drug delivery with a carrier into the targeted organelles (nucleus, mitochondria, lysosomes, etc.) is vital for achieving effective disease treatment. Nanoparticle (NP) based drug delivery systems (NDDSs) depend on targeted delivery and are mainly focused on cell-membrane targeting. In this review, we summarize research on multifunctional NPs with organelle-specific drug delivery. Different effective strategies are proposed for these nanoparticles functionalizing by altering their chemical composition or by functional groups grafting onto their surface for improving the ability of organelle targeting. Only when the released concentration of drugs becomes high enough will they interact with specific organelles by molecular targets to induce apoptosis of tumor cells. One of the prime goals for drug delivery research targeted is Organelle-specific delivery.\u0000","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43275930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-20DOI: 10.2174/2468187313666221020143555
N. Jawahar, S. Aravind, Bala Sai Soujith Nidamanuri, Praharsh Kumar M R, S. V, J. Selvaraj
Tobacco smoking is a major factor leading to cardiovascular diseases. About 48% of cardiovascular diseases occur due to cigarette smoking. Bupropion Hydrochloride is non-nicotine treatment for smoking cessation. The existing marketed formulation of bupropion have limitations like low bioavailability and extensive first-pass metabolism. In order to boost the bioavailability and increase the brain biodistribution of the drug, a colloidal drug delivery system like nanostructured lipid carriers is employed. NLC formulation was prepared using microemulsion technique and optimized formula was developed using three-level factorial design. The particle size of the optimized formulation was 162 nm, Polydispersity index was 12.2% and zeta potential was -29.0mV. Entrapment efficiency was found to be 41.2%. SEM images show that these NLCs are spherical. In-vitro drug release study was conducted and at the end of 72 hours, 50 % of drug was released, indicates the sustained release of drug. Histopathological studies were conducted using goat nasal mucosa and results indicates that NLC formulation is non-toxic for intranasal administration. Thus, through intra-nasal route an increased concentration of drug can be delivered to the brain via olfactory pathway and improve the therapeutic effect and better patient compliance in smoking cessation.
{"title":"Formulation, Optimization and Characterization of Bupropion Hydrochloride Loaded Nanostructured Lipid Carriers for Intra-Nasal Administration: An Approach for Management of Smoking Cessation","authors":"N. Jawahar, S. Aravind, Bala Sai Soujith Nidamanuri, Praharsh Kumar M R, S. V, J. Selvaraj","doi":"10.2174/2468187313666221020143555","DOIUrl":"https://doi.org/10.2174/2468187313666221020143555","url":null,"abstract":"\u0000\u0000Tobacco smoking is a major factor leading to cardiovascular diseases. About 48% of cardiovascular diseases occur due to cigarette smoking. Bupropion Hydrochloride is non-nicotine treatment for smoking cessation. The existing marketed formulation of bupropion have limitations like low bioavailability and extensive first-pass metabolism. In order to boost the bioavailability and increase the brain biodistribution of the drug, a colloidal drug delivery system like nanostructured lipid carriers is employed.\u0000\u0000\u0000\u0000NLC formulation was prepared using microemulsion technique and optimized formula was developed using three-level factorial design.\u0000\u0000\u0000\u0000The particle size of the optimized formulation was 162 nm, Polydispersity index was 12.2% and zeta potential was -29.0mV. Entrapment efficiency was found to be 41.2%. SEM images show that these NLCs are spherical. In-vitro drug release study was conducted and at the end of 72 hours, 50 % of drug was released, indicates the sustained release of drug. Histopathological studies were conducted using goat nasal mucosa and results indicates that NLC formulation is non-toxic for intranasal administration.\u0000\u0000\u0000\u0000Thus, through intra-nasal route an increased concentration of drug can be delivered to the brain via olfactory pathway and improve the therapeutic effect and better patient compliance in smoking cessation.\u0000","PeriodicalId":10818,"journal":{"name":"Current Nanomedicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41888279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：